Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury
Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).
Phase:
PHASE1
Details
Lead Sponsor:
Hope Biosciences LLC
Collaborators:
The University of Texas Health Science Center, Houston University of Alabama at Birmingham University of California, San Francisco